Cangfu daotan decoction for polycystic ovary syndrome
Open Access
- 1 September 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (39) , e17321
Abstract
Polycystic ovary syndrome (PCOS) is common endocrine disorder in women and can lead to serious social burdens associated with various reproductive and metabolic abnormalities. Existing therapy is controversial in its effectiveness including side effects. In traditional Korean Medicine, Cangfu Daotan Decoction (CDD), also known as Changbudodam-tang, is used for PCOS patients who are in the type of stagnation of phlegm and dampness. In this study, we aimed to evaluate the efficacy and safety of CDD for PCOS as alternative treatment. Two researchers will search the following databases from their inception to February 2019 for relevant randomized controlled trials (RCTs): The Cochrane Library, PubMed, EMBASE, Chinese National Knowledge Infrastructure Database (CNKI), and 5 Korean medical databases (Korean Studies Information Service System, KoreaMed, DBPIA, Oriental Medicine Advanced Searching Integrated System, and Research Information Service System). The primary outcome will be the scales that assessed drug efficacy including total response rate, sex hormone level (LH, FSH, Testosterone, LH/FSH ratio), BMI, ovulation rate, and pregnancy rate. Adverse events will be assessed as the secondary outcome. Study selection, data extraction, and assessment of risk of bias will be conducted by 2 researchers independently. Statistical analysis will be performed by using the Cochrane Review Manager (RevMan 5.3) software. This review will provide the latest knowledge and evidence on the efficacy and safety of CDD for PCOS women through the analysis of various evaluation scales. This systematic review does not require ethical approval and will be published in a peer-reviewed journal. CRD42019134270.Keywords
This publication has 20 references indexed in Scilit:
- PharmDB-K: Integrated Bio-Pharmacological Network Database for Traditional Korean MedicinePLOS ONE, 2015
- Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary SyndromeEndocrine Reviews, 2015
- Adverse Effects of the Common Treatments for Polycystic Ovary Syndrome: A Systematic Review and Meta-AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2013
- 20 µg versus >20 µg estrogen combined oral contraceptives for contraceptionCochrane Database of Systematic Reviews, 2013
- Cancer risk and PCOSSteroids, 2013
- Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysisReproductive Biology and Endocrinology, 2013
- Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) SocietyThe Journal of Clinical Endocrinology & Metabolism, 2010
- Polycystic ovary syndrome and its impact on women’s quality of life: More than just an endocrine disorderDrug, Healthcare and Patient Safety, 2009
- Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary SyndromeNew England Journal of Medicine, 2007
- Overweight Women with Polycystic Ovary Syndrome Have Evidence of Subclinical Cardiovascular DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2005